ArticleAAPS PharmSciTech2013
Development of novel elastic vesicle-based topical formulation of cetirizine dihydrochloride for treatment of atopic dermatitis.
Article in AAPS PharmSciTech, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Topical delivery of l-ascorbic acid spanlastics for stability enhancement and treatment of UVB induced damaged skin.Drug delivery · 2021Trial
- Targeted transferosomal delivery of cetirizine: A new approach to alopecia management.PloS one · 2026Article
- Novel drug delivery systems in topical treatment of atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Application of 3Scientific reports · 2024Article
- Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis.Pharmacological reports : PR · 2023Review
- Formulation optimization,Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Targeting therapeutic approaches and highlighting the potential role of nanotechnology in atopic dermatitis.Environmental science and pollution research international · 2022Review
- Article
- Brain Targeting of Citicoline Sodium via Hyaluronic Acid-Decorated Novel Nano-Transbilosomes for Mitigation of Alzheimer's Disease in a Rat Model: Formulation, Optimization, in vitro and in vivo Assessment.International journal of nanomedicine · 2022Article
- Gallic Acid Ameliorates Atopic Dermatitis-Like Skin Inflammation Through Immune Regulation in a Mouse Model.Clinical, cosmetic and investigational dermatology · 2021Article
- Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature.Bioactive materials · 2019Review
- Improved transdermal delivery of cetirizine hydrochloride using polymeric microneedles.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Article
- Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems.International journal of molecular sciences · 2019Review
- Combination Effect of Titrated Extract ofAllergy, asthma & immunology research · 2019Article
- Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene.PloS one · 2019Article
- Vesicular carriers containing phenylethyl resorcinol for topical delivery system; liposomes, transfersomes and invasomes.Asian journal of pharmaceutical sciences · 2018Article
- Increased skin permeation efficiency of imperatorin via charged ultradeformable lipid vesicles for transdermal delivery.International journal of nanomedicine · 2018Article
- Elastic liposomes as novel carriers: recent advances in drug delivery.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cetirizine is a piperazine-derived second-generation antihistaminic drug recommended for treatment of pruritus associated with atopic dermatitis. The present investigation encompasses development of a nanosized novel elastic vesicle-based topical formulation of cetirizine dihydrochloride using combination of Phospholipon® 90G and edge activators with an aim to have targeted peripheral H1 antihistaminic activity. The formulation was optimized with respect to phospholipid/drug/charge inducer ratio along with type and concentration of edge activator. The optimized formulation was found to be satisfactory with respect to stability, drug content, entrapment efficiency, pH, viscosity, vesicular size, spreadability, and morphological characteristics. The ex vivo permeation studies through mice skin were performed using Franz diffusion cell assembly. It was found that the mean cumulative percentage amount permeated in 8 h was almost twice (60.001 ± 0.332) as compared to conventional cream (33.268 ± 0.795) and aqueous solution of drug (32.616 ± 0.969), suggesting better penetration and permeation of cetirizine from the novel vesicular delivery system. Further, therapeutic efficacy of optimized formulation was assessed against oxazolone-induced atopic dermatitis in mice. It was observed that the developed formulation was highly efficacious in reducing the itching score (4.75 itches per 20 min) compared to conventional cream (9.75 itches per 20 min) with profound reduction in dermal eosinophil count and erythema score. To conclude, a novel vesicular, dermally safe, and nontoxic topical formulation of cetirizine was successfully developed and may be used to treat atopic dermatitis after clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.